Patient-Based Therapeutics

AcuraStem is a near-to-clinic, patient-based, biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

get to know us

Patient Focused

rp3.jpgrp1.jpgrp2.jpg

rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 


learn about our work

Neurodegenerative Disease Areas

Latest News

November 3, 2019

Walk to Defeat ALS, Golden West Chapter

Nov 3rd, 2019, Walk to Defeat ALS, Golden West Chapter: Team AcuraStem is fundraising for Team Nanci and the whole team will walk in LA on November 3rd. Come by our booth!

» Read more
October 26, 2019

AcuraStem CEO Invited to be Guest Panelist at BCLA Biotech Summit on Oct. 26.

October 26th, 2019, UCLA California NanoSystems Institute: CEO, Co-Founder Sam Alworth Presenting at the 5th Annual BCLA Biotech Summit "Mapping out LA’s Biotech Landscape"

» Read more
October 22, 2019

AcuraStem Triggers $3M Phase II Fast Track SBIR Grant to Accelerate Preclinical Development of its AS-1 Program for ALS

AcuraStem announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

» Read more

Keep Up to Date with AcuraStem